# ACCRU-GI-1617 (NCT03043313)

> Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03043313
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Seagen Inc.
- Conditions: Metastatic Colorectal Adenocarcinoma
- Interventions: Trastuzumab; Tucatinib
- Enrollment: 117
- Primary outcome: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 70
- X threads: 57
- YouTube: 48
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=accru-gi-1617-nct03043313

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03043313", "email": "<work email>"}; the inbox owner confirms by the emailed link.